Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

The company's blockbuster semaglutide drugs ... a hit of $1.26 billion this year from debt financing. Injection pens and boxes of Novo Nordisk's weight-loss drug Wegovy are shown in this photo ...

Taking aim at the sky-high price of semaglutide, Medicare plans to negotiate prices for Novo Nordisk products Ozempic (an injection to control diabetes), Wegovy (an injection more designed for ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. In the phase 3b ...

plus weight-loss injection Wegovy. Combined, semaglutide sold under these three brands is expected to become the world’s top-selling medicine in 2024. Novo Nordisk “has significant concerns ...

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk is under pressure from investors ... be more powerful than its blockbuster weight-loss injection Wegovy, but investors are worried whether ...

16.1% with semaglutide 2.4 mg and 2.3% with placebo alone. Also Read: Novo Nordisk's Higher Dose Of Wegovy Shows Roughly 21% Weight Loss In interviews with Reuters, some investors, analysts ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide ... compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold ...